Uncategorized

Tamoxifen As A Breast Cancer Treatment

Tamoxifen As A Breast Cancer Treatment

Tamoxifen has been approved for use in treatment of advanced breast cancer since 1973 in the United Kingdom and 1977 in the United States. This followed the report by Cole in 1971 of a 22% response rate with Nolvadex, the citrate salt of tamoxifen. Since 1971, tamoxifen has been used for more than 10 million patient-years worldwide.

It is one of the safest, cheapest, best-tolerated, and most effective of all cancer treatments. Until recently, it has been the first-line treatment for endocrine-responsive advanced breast cancer, and it remains the treatment of choice for early invasive cancer of breast and Pre-invasive breast cancer or duct carcinoma in situ (DCIS). It has also been shown to reduce the incidence of contralateral cancer of breast after a diagnosis of invasive breast cancer as well as reducing the occurrence of first clinical cancer of breast in women considered to be at increased risk.

Tamoxifen As A Breast Cancer Treatment

Tamoxifen, therefore, is widely used clinically for treatment of early and advanced disease, DCIS, and prevention. The U.S. Food and Drug Administration (FDA) approved usages include adjuvant therapy in postmenopausal women with nodepositive cancer of breasts with chemotherapy (1985) and alone (1986); in Pre-menopausal women with estrogen receptor-positive advanced cancer (1989); as adjuvant treatment for pre- and postmenopausal women with node-negative estrogen receptor-positive cancer of breasts (1990); for reduction of risk of breast cancer in high-risk pre- and postmenopausal women (1998); and for adjuvant treatment of ductal carcinoma in situ after surgery and radiotherapy to reduce the incidence of invasive cancer (2001).

Tamoxifen is clearly a pillar of cancer of breast control and has made a substantial contribution to the reduced mortality rate that has been reported in several developed countries since 1990. It will require substantial and strong evidence of efficacy, tolerability, and safety before tamoxifen is replaced by alternative treatments for women with endocrine-responsive cancer.

Tamoxifen As A Breast Cancer Treatment

Leave a Reply

Your email address will not be published. Required fields are marked *